行情

CBAY

CBAY

CymaBay
NASDAQ

实时行情|Nasdaq Last Sale

1.900
0.000
0.00%
盘后: 1.900 0 0.00% 16:00 01/24 EST
开盘
1.910
昨收
1.900
最高
1.940
最低
1.860
成交量
86.29万
成交额
--
52周最高
14.00
52周最低
1.290
市值
1.31亿
市盈率(TTM)
-1.3264
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CBAY 新闻

  • 摩根大通CEO:当前金融市场唯一泡沫是主权债
  • 新浪财经综合.3天前
  • 特朗普称赞马斯克是当代爱迪生:必须保护的伟大天才
  • 新浪财经.3天前
  • 美股尾盘回吐涨幅 科技股表现出色 苹果特斯拉创新高
  • 一财网.3天前
  • 隔夜要闻:特朗普再对欧洲施压 加央行维持利率不变
  • 新浪美股.3天前

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

CBAY 简况

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
展开

Webull提供CymaBay Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。